PCM
SAGE

Penserra Capital Management’s Sage Therapeutics SAGE Stock Holding History

Penserra Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,345
Closed -$59K – 1527
2021
Q3 		$59K Buy
1,345
+15
+1% +$688 ﹤0.01% 1002
2021
Q2 		$75K Buy
1,330
+10
+0.8% +$707 ﹤0.01% 884
2021
Q1 		$98K Buy
1,320
+125
+10% +$10.2K ﹤0.01% 689
2020
Q4 		$103K Buy
+1,195
New +$88.1K ﹤0.01% 598

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Penserra Capital Management's SAGE Position: Q4 2021 in Review

Penserra Capital Management sold out of Sage Therapeutics (SAGE) in Q4 2021, closing a stake of 1,345 shares — an estimated $59K sold.

Penserra Capital Management first reported a position in SAGE in Q4 2020 and held it in 4 quarters. The position peaked at $103K in Q4 2020. 216 funds tracked by Wall St. Rank hold SAGE as of Q4 2021.

  • Penserra Capital Management reported no remaining Sage Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,345 Sage Therapeutics shares in Q4 2021, an estimated $59K.
  • Penserra Capital Management first reported a position in Sage Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Sage Therapeutics position peaked at $103K in Q4 2020.
  • 216 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.